ClinicalTrials.gg
Enrolling by invitationNCT06979024Updated May 18, 2025

A Registered Observational Cohort Study of Myotonic Dystrophy Type 1

An observational study in Myotonic Dystrophy Type 1 (DM1), sponsored by First Affiliated Hospital of Fujian Medical University. Enrolling by invitation at 1 site in China. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by First Affiliated Hospital of Fujian Medical University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Sex
All
01

Study summary

Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy.There is little phenotype and genetic data for Chinese DM1 patients. The data to be collected is intended to fill this gap and provide complementary data

Read the detailed description

Myotonic dystrophy 1 (DM1) is an autosomal, dominantly inherited neuromuscular disorder characterized by skeletal muscle weakness, myotonia, cardiac conduction abnormalities, cataracts, and other abnormalities. The China DM1 patient registry is a nationwide, population-based, non-interventional, observational cohort clinical study of all age groups of genetically-confirmed DM1 patients from families (with at least 1 affected member), collecting data retrospectively at study entry and prospectively during follow up. Currently, there is limited phenotype and genotype data available for DM1 patients with Chinese Han ethnicity. Therefore, the data to be collected is intended to fill this gap and provide complementary data.

02

Conditions studied

  • Myotonic Dystrophy Type 1 (DM1)

Browse trials for

Keywords

  • Myotonic Dystrophy Type 1
  • Tandem repeat
03

In context

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

This study's planned enrollment of 300 is above the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.

Browse Myotonic Dystrophy studies →

Lead sponsor

First Affiliated Hospital of Fujian Medical University is the lead sponsor of 97 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All genetically-confirmed DM1 patients from families (with at least 1 affected member) in China, irrespective of age. The CTG repeats presented at least 50 repeats in DMPK gene, the diagnosis of which was performed at Fujian Neuromedical Center (FNMC), the clinical genetic test hospital for DM1 in China to employ triplet-primed PCR or long-read sequencing technology.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects of all ages at baseline
  • Subjects, with or without symptoms, with DM1 genetic confirmation through triplet-primed PCR or long-read sequencing
  • Unrelated healthy controls

Exclusion criteria

Exclusion Criteria:

  • Decline to participate
  • Other neuromuscular disease (such as Limb-girdle muscular dystrophy or Oculopharyngodistal Myopathy)
  • Serious systemic illness (such as heart, liver, kidney disease or major mental illness)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort of Patients with Myotonic Dystrophy Type 1 (DM1)

    This cohort includes patients with Myotonic Dystrophy Type 1 (DM1), focusing on clinical observations to understand the natural progression of the disease. Observations cover changes in muscle function, respiratory capacity, cardiac health, and quality of life. Additionally, third-generation sequencing is used to determine repeat numbers, exploring the relationship between repeat expansion and clinical phenotypes. These insights aim to identify biomarkers of disease progression and provide foundational data for future therapeutic research.

    Genetic: Triplet-primed PCR or Long-read sequencing

Interventions

  • GeneticTriplet-primed PCR or Long-read sequencing

    This study involves long-read sequencing in patients with Myotonic Dystrophy Type 1 (DM1) to identify specific motifs, determine the range of repeat numbers, and assess the presence of interruptions in the CTG repeat sequence. The aim is to gain insights into the genetic variability and its clinical implications in DM1.

06

What researchers measure

Primary outcomes

  1. Triplet-primed PCR or Long-read sequencing

    Genetic test of triplet-primed PCR or long-read sequencing is performed for these clinical suspected DM1 patients on the basis of the family as a whole. Eligible participants are genetically confirmed patients With CTG repeats \>50 in DMPK gene.

    Time frame: Baseline

  2. Muscle Impairment Rating Scale (MIRS)

    This scale evaluates muscular impairment severity according to an ordinal 5-point scale as follows: (1) no muscular impairment, (2) minimal signs, (3) distal weakness, (4) mild to moderate proximal weakness, and (5) severe proximal weakness.

    Time frame: Baseline through study completion (an average of 1 year)

  3. The modified Medical Research Council (MRC) scale

    The modified Medical Research Council (MRC) scale is used to assess numerically the muscle strength of DM1 participants. Firstly, muscles are tested bilaterally (when applicable) in standardized positions with manual muscle testing (MMT) scores. Then, MMT scores are converted to calculable data of the modified MRC scale.

    Time frame: Baseline through study completion (an average of 1 year)

Secondary outcomes

  1. Changes in 6-Minute Walk Test

    The 6-Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered in 6 minutes serves as the outcome for comparing changes in performance capacity.

    Time frame: Baseline through study completion (an average of 1 year)

  2. Changes in 10 Metre Walk Test (10MWT)

    The 10 Metre Walk Test is a performance measure used to assess walking speed in meters per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function.

    Time frame: Baseline through study completion (an average of 1 year)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Requests for IPD will be evaluated on a case-by-case basis.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2008 (actual). Primary completion is estimated for Dec 2038, 371 months after the start.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 371 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 18, 2025
StartActual
Jan 2008
Primary completionEst.
Dec 2038
CompletionEst.
Dec 2038
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06979024
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Responsible party
Sponsor
First posted
May 18, 2025
Start date
Jan 2008
Primary completion
Dec 2038 (estimated)
Completion
Dec 2038 (estimated)
Last update
May 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion